Both in Biotechnology
Humacyte vs Compass Therapeutics
Over the past year HUMA returned −71.9% and CMPX returned −79.4%; their daily moves had a correlation of -0.01.
HUMA −71.9% CMPX −79.4%Growth of $1, one year, split-adjusted
| Metric | HUMA | CMPX |
|---|---|---|
| Price | $0.4465 | $0.7720 |
| Market cap | $124.0M | $139.0M |
| Today | +1.36% | +2.52% |
| 1 month | −6.6% | −22.7% |
| 6 months | −54.6% | −58.7% |
| Year to date | −53.5% | −85.6% |
| 1 year | −71.9% | −79.4% |
| Revenue growth (YoY) | +34.9% | — |
| Gross margin | −203.2% | — |
| Net margin | −9064.5% | — |
| P/E (TTM) | — | — |
| Price / sales | 58.5× | — |
| Net cash | $13.7M | $179.9M |
| Dividend yield | — | — |
| Volatility (60d) | 107.8% | 100.7% |
| Short % of float | 11.9% | 33.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).